Skip to main content
SURAKSHA · Health Care · 2026-08-21

Suraksha Diagnostic Ltd

Stage 4 · wk 6In scan: Breakout WatchMARKET: BULL RISING · 2026-08-21
₹325.8
+6.77% today
₹1,697 Cr · Small cap
About this companyHealth Care· Hospitals & Diagnostic Centres
Expand ▾

Suraksha Diagnostic Limited operates a chain of diagnostic centers in India. It offers pathology testing services, such as microbiology, serology, molecular biology, histopathology, cytopathology, clinical pathology, and haematology; genomics testing, including microarray, noninvasive prenatal, quantitative fluorescent polymerase chain reaction, fluorescence in situ hybridization, and karyotyping; and radiology testing that includes X ray, magnetic resonance imaging, computed tomography scan, USG, DEXA scan, OPG, and mammography. The company also provides Cardiology testing services comprises electrocardiogram, echocardiogram, stress test / treadmill test, wireless holter monitoring, colour doppler, peripheral doppler, and pulmonary function test; gastroenterology, such as upper and lower GI endoscopy, sigmoidoscopy, proctoscopy, colonoscopy, and proctosigmoidoscopy; and neurology testing services, including electroencephalogram, electromyography, and nerve conduction velocity test. In addition, the company provides dental, physiotherapy, immunology & rheumatology, eye, fetal care, ENT, and speciality clinics, as well as home doctor visit services. The company was founded in 1992 and is based in Kolkata, India.

Visit company website →
P/E (TTM)
46.3
Forward 31.5
Earnings Growth (YoY)
-5.4%
Revenue +31.2%
ROE
+13.8%
Profit margin +10.4%
Dividend Yield
0.17%
P/B 6.5
vs 52W High
-0.6%
₹228 lo₹327.9 hi
0.6% below 52W high — failed near resistance
In Stage 4, distance from the 52W high reflects ongoing decline — not a discount. Avoid catching falling knives.
Stage Maturity
Week 6
1w13w26w
Week 6 — early Stage 4 decline
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure — there's no 'bottom' time to buy.
vs 200 DMA
17.6%
200 DMA: ₹277.2 · sloping down
In Stage 4, the stock is below its 200 DMA — the hallmark of a downtrend. No long positions warranted until this reverses structurally.
Rel Volume
1.11x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low volume bounces are typical — they lack real buyers and should not be mistaken for reversals.
Trend Health
↑ ⇈
Accelerating · MA20 +7.4% vs MA50 -2.5% / 10d
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
55.5%
20d Δ
+3.9pp
1M return
+2.7%
3M return
+9.6%
Sector Stage-2 % · last 20 days
Sector has 84 Stage 2 leaders. See Health Care Stage 2 →
Industry
Hospitals & Diagnostic Centres
↓ Peaking
Stage 2%
55.6%
20d Δ
-7.4pp
1M return
-2.8%
3M return
+2.0%
Industry Stage-2 % · last 20 days
Industry has 15 Stage 2 leaders. See Hospitals & Diagnostic Centres Stage 2 →
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2024-12-06 → 2026-08-21
S? 42w
S4 22w
S1 10w
2024-12-062026-08-21
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 42w → S4 6w → S2 4w → S4 22w → S1 10w → S4 6w current
Total tracked: 89 weeks across 6 stage runs.
1M
+25.5%
3M
+4.0%
6M
+14.4%
YTD
+22.7%
1Y
+8.1%
Scan Membership
Breakout Watch
Latest: 2025-11-06
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-21S4
Wk 6 · Vol x
2026-08-20S4
Wk 6 · Vol x
2026-08-19S4
Wk 6 · Vol x
2026-08-18S4
Wk 6 · Vol x
2026-08-17S4
Wk 5 · Vol x
2026-08-14S4
Wk 5 · Vol x
2026-08-13S4
Wk 5 · Vol x
2026-08-12S4
Wk 5 · Vol x
2026-08-11S4
Wk 5 · Vol x
2026-08-10S4
Wk 4 · Vol x
2026-08-07S4
Wk 4 · Vol x
2026-08-06S4
Wk 4 · Vol x
Sector Peers — Stage 2All →
NEULANDLAB
wk 12 · -1.5% from hi
9.0
ALIVUS
wk 19 · -3.4% from hi
9.0
DIVISLAB
wk 14 · -0.0% from hi
8.8
SAILIFE
wk 25 · -1.0% from hi
8.8
SHILPAMED
wk 15 · -0.9% from hi
8.6
Moving averages & range
50 DMA
₹269
200 DMA
₹277.2
52W High
₹327.9
52W Low
₹228
5D Low
₹305.2
Resistance levels (recent highs)
20d High
₹325.8
60d High
₹325.8
120d High
₹325.8
250d High
₹327.9
Next resistance
+0.6%
to 250d High

All analytics based on EOD data. Data as of 2026-08-21. Past data patterns are not indicative of future results. This page is a data analytics tool only.